[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100418633":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":38,"locations":47,"responsibleParty":65,"collaborators":67,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":11,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":11,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Association de Recherche Bibliographique pour les Neurosciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Parkinson's disease (mild to moderate stage)","EXPERIMENTAL",null,[13],"Other: Video-oculography \u002F Neuropsychological evaluations",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Video-oculography \u002F Neuropsychological evaluations","Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET\u002FCT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.",[9],[20,24,28,32,35],{"name":21,"affiliation":22,"role":23},"Philippe BARRES, MD","Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco.","STUDY_DIRECTOR",{"name":25,"affiliation":26,"role":27},"Sandrine LOUCHART DE LA CHAPELLE, MD-PHD","Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":31},"Alain PESCE, PUPH","AREBISN (Association de Recherche Bibliographique pour les Neurosciences), Nice (France)","STUDY_CHAIR",{"name":33,"affiliation":34,"role":27},"Caroline GIORDANA, MD","Centre Expert Parkinson, Unités des Pathologies du Mouvement, Hôpital Pasteur 2, Nice (France)",{"name":36,"affiliation":37,"role":27},"Benoit PAULMIER, MD","Médecine Nucléaire, Princess Grace Hospital, Monaco.",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Solange HESSE","CONTACT","+377 99995599","solange.hesse@chpg.mc",{"name":45,"role":41,"phone":11,"phoneExt":11,"email":46},"Kévin POLET","kevin.polet@chpg.mc",[48],{"facility":49,"status":50,"city":51,"state":11,"zip":52,"country":51,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Centre Mémoire \u002F Centre de Gérontologie Clinique Rainier III \u002F Princess Grace Hospital","RECRUITING","Monaco","98000","MC",{"type":55,"coordinates":56},"Point",[57,58],7.42145,43.73718,{"lat":58,"lon":57},[61,62,64],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},{"name":63,"role":41,"phone":11,"phoneExt":11,"email":46},"Kevin POLET",{"name":25,"role":27,"phone":11,"phoneExt":11,"email":11},{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[68,70],{"name":69,"class":6},"Centre Hospitalier Princesse Grace",{"name":71,"class":6},"Centre Hospitalier Universitaire de Nice","100418633","video-oculography-and-parkinsons-disease-100418633",false,"NCT04731246","Video-oculography and Parkinson's Disease","Video-oculography and Parkinson's Disease: A Prospective Study","\\*Inclusion Criteria:\n\n1. Male or Female;\n2. Clinically defined idiopathic Parkinson's Disease (PD);\n3. Brain MRI performed in routine care in the 12 months preceding inclusion;\n4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;\n5. Hoehn \\& Yahr score: 1 to 3;\n6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted);\n7. Neuro-cognitive disorders: absent or minor (according to DSM5);\n8. Sufficient written and oral expression in French;\n9. Covered by a health insurance system;\n10. Written informed consent signed by the patient;\n11. Presence of a caregiver.\n\n    \\* Exclusion Criteria:\n12. Psychiatric comorbidity (except anxiety or mild to moderate depression);\n13. Neurological comorbidity, if significant;\n14. Brain MRI showing:\n\n    1. significant cerebrovascular pathology (Fazekas I admitted),\n    2. another brain disease, including stroke.\n15. Major cognitive impairment;\n16. Absolute exclusion criteria and \"Red flags\" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system:\n\n    * Cerebellar syndrome\n    * Vertical oculomotricity disorders on clinical examination\n    * Motor symptoms restricted to the lower limbs\n    * Bilateral and perfectly symmetrical parkinsonism\n    * Early dystonia\n    * Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD)\n    * Progressive aphasia or apraxia\n    * Moderate or severe postural instability and \u002F or early falls\n    * Early bulbar dysfunction (dysarthria, swallowing disorders)\n    * Ventilatory dysfunction (inspiration)\n    * Severe dysautonomia\n    * DOPA-resistance\n    * Neuroleptic treatment or related\n17. Normal MIBG myocardial scintigraphy (if performed).","ALL","18 Years",{"count":82,"type":83},30,"ESTIMATED","INTERVENTIONAL",[86],"NA","This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015):\n\n* the evolution of oculomotricity markers over time.\n* the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years.\n* the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography.\n* the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.",[89],"Parkinson Disease, Idiopathic",[91,92,93,94,95,96,97,98],"Parkinson's disease","Video-oculography","Oculomotor disorders","Oculomotricity","Neuropsychological evaluations","Movement disorder","Motor disorders","Non-motor fluctuations","2025-09-30",{"date":101,"type":102},"2025-10-01","ACTUAL",{"date":104,"type":102},"2021-07-07",{"date":106,"type":83},"2032-01",{"name":5,"class":6},1]